Regenxbio IncChange company Symbol lookupSelect an option...RGNX Regenxbio IncSGBXV Safe & Green Holdings CorpGOOG Alphabet IncWHLR Wheeler Real Estate Investment Trust IncFRHLF Freehold Royalties LtdCTNT Cheetah Net Supply Chain Service IncLASE Laser Photonics CorpGFR M3-Brigade Acquisition III CorpPCT Purecycle Technologies IncUPST Upstart Holdings IncGo
REGENXBIO Inc. is a clinical-stage biotechnology company, which is focused on providing curative potential of gene therapy. Its investigational gene therapies are designed to deliver functional genes to address genetic defects in cells. The Company’s investigational AAV Therapeutics include RGX-314, RGX-202, RGX-121, RGX-111 and RGX-181 and RGX-381. RGX-314 is meant for the treatment of large patient populations impacted by wet age-related macular degeneration (wet AMD), diabetic retinopathy and other chronic retinal diseases. RGX-202 is developed to treat Duchenne muscular dystrophy, one of the common fatal genetic disorders affecting children. RGX-121, RGX-111 and RGX-181 are developed to treat Mucopolysaccharidosis type II, Mucopolysaccharidosis type I, and late infantile neuronal ceroid lipofuscinosis type II (CLN2 disease), all of which are progressive, neurodegenerative lysosomal storage disorders. RGX-381 is developed to treat the ocular manifestations of CLN2 disease.
|
|
|
|
| |
Upcoming Events
Past Earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
| Date | Event description | Earnings per share actual | Earnings estimate range | Previous year's actual |
|---|---|---|---|---|
| August 2, 2023 | Q2 2023 Earnings Release | -$1.66 | -$1.55 to -$1.20 | -$1.58 |
| May 3, 2023 | Q1 2023 Earnings Release | -$1.53 | -$1.77 to -$1.28 | -$1.79 |
| February 28, 2023 | Q4 2022 Earnings Release | -$1.38 | -$1.67 to -$0.22 | $6.67 |
| November 3, 2022 | Q3 2022 Earnings Release | -$1.75 | -$1.56 to -$1.37 | -$1.37 |
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.